Physician profile
Shahab Mehdizadeh
NPI 1790715241
$162,949.26
in general payments reported to CMS, 2019-2025
22 companies · $6,813 in 2025
The $6,813 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $43K · 2021: $41K · 2022: $17K · 2023: $13K · 2024: $17K · 2025: $6,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $2,061 · Travel and Lodging: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,775.00 |
| Food and Beverage | $2,061.24 |
| Travel and Lodging | $1,389.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $160,025.01 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,360.72 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Qol Medical, LLC | $273.02 | 2021-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $208.52 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $192.24 | 2019-2025 | Tremfya, Remicade, Simponi |
| Redhill Biopharma INC. | $138.11 | 2020-2022 | |
| Tersera Therapeutics LLC | $109.84 | 2020-2023 | Xermelo |
| Novo Nordisk INC | $105.01 | 2022 | |
| Ironwood Pharmaceuticals, INC | $82.78 | 2023-2024 | Linzess |
| Merck Sharp & Dohme LLC | $76.45 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $48.16 | 2019-2023 | Rebyota |
| Concordia Pharmaceuticals INC. | $45.19 | 2019 | |
| Genzyme Corporation | $39.42 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $38.70 | 2019 | |
| Alfasigma USA, INC. | $31.15 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $30.60 | 2025 | Vowst |
| Linvatec Corporation | $28.25 | 2024 | Linvatec Shoulder Arthroscopy, Hall Power, Allograft Tissue |
| Intercept Pharmaceuticals, INC. | $25.31 | 2021 | |
| Celgene Corporation | $23.44 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.99 | 2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $22.64 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahab Mehdizadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.